|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments (amortized cost of $307,394) | ||||||||||||||||||||
| Grants receivable | ||||||||||||||||||||
| Research and development tax credits receivable | ||||||||||||||||||||
| Refundable income taxes | ||||||||||||||||||||
| Unbilled milestone receivable | ||||||||||||||||||||
| Milestone receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Long-term investments (amortized cost of $74,475) | ||||||||||||||||||||
| Research and development tax credits receivable, net of current portion | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Right of use assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Income tax payable | ||||||||||||||||||||
| Other accrued expenses | ||||||||||||||||||||
| Accrued clinical trial costs | ||||||||||||||||||||
| Accrued personnel expenses | ||||||||||||||||||||
| Payable for investments | ||||||||||||||||||||
| Deferred income | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Grants repayable, net of current portion | ||||||||||||||||||||
| Lease liabilities, net of current portion | ||||||||||||||||||||
| Unrecognized tax benefits | ||||||||||||||||||||
| Other noncurrent liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock, $0.001 par value; 10,000,000 and zero shares authorized at September 30, 2022 and December 31, 2021,and zero shares issued or outstanding | ||||||||||||||||||||
| Common stock, $0.001 par value: 150,000,000 shares authorized at March 31, 2025 and December 31, 2024; 38,271,682 and 36,598,043 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
